Thyrocare Shares Fall 8% After Promoter Sells 10% Stake

shares fell nearly 8% after promoter Docon Technologies sold around 10% of the company's paid-up equity capital, triggering concerns over promoter stake reduction and near-term supply pressure. Key Details Shares Sold: 53.33 lakh shares Stake Sold: ~10% of paid-up capital Transaction Value: ₹667.69 crore Average Selling Price: ₹1,252.03 per share Promoter Holding: Reduced to 60.93% from 70.98% Docon: Continues to remain a promoter of Thyrocare. Why Did the Stock Fall? The immediate pressure is largely supply-driven. A promoter selling such a sizeable stake increases the available shares in the market and can weigh on investor sentiment, particularly when the transaction is executed at a substantial scale. However, the important point is that Docon has not exited the company. It continues to hold a majority stake of around 61%, so the transaction does not represent a change in control. There is also a broader financing context. Docon's shares in Thyrocare have been used as security for borrowings at the API Holdings level, with the company's filings showing the promoter stake remains pledged in connection with the refinancing arrangements.